AbbVie blockbuster fails in pancreatic cancer study
AbbVie said its blockbuster cancer treatment, Imbruvica, in combination with chemotherapy agents, failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Pharmaceuticals | Study